Evaluate Vantage Homepage
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.